Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,025 across all filing types
Latest filing 2025-07-17 Regulatory Filings
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
TRANSACTION IN OWN SHARES
Regulatory Filings
2025-07-17 English
GSK’s Shingrix Fully Liquid FDA approval
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 3829R' and concludes with information about RNS, the news service of the London Stock Exchange, stating it is approved by the Financial Conduct Authority to act as a Primary Information Provider. The content itself is a press release announcing that the US FDA approved a prefilled syringe presentation of GSK's Shingrix vaccine. This is a general, time-sensitive corporate announcement distributed via a regulatory news service, but it is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific shareholder document (like DEF 14A or DVA). Since it is a general regulatory announcement distributed through the RNS system and doesn't fit the more specific categories (like ER, CAP, DIV, etc.), the most appropriate classification is the general regulatory filing fallback category.
2025-07-17 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document text explicitly states it is an announcement regarding a 'Transaction in own shares' by GSK PLC on July 17, 2025, detailing the purchase of 482,507 ordinary shares on July 16, 2025, as part of an existing buyback programme. This directly matches the definition for 'Transaction in Own Shares' (Code: POS), which covers company share repurchases.
2025-07-17 English
TRANSACTION IN OWN SHARES
Regulatory Filings
2025-07-16 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document text begins with 'National Storage Mechanism | Additional information RNS Number : 1934R GSK PLC 16 July 2025 Transaction in own shares GSK plc...'. The key phrases are 'Transaction in own shares' and the mention of an 'RNS Number'. This clearly indicates a regulatory filing detailing the company's purchase of its own shares (a share repurchase program). This aligns perfectly with the definition for 'Transaction in Own Shares' (Code: POS). Although it is a regulatory filing, POS is more specific than RNS or DIRS (which is for director's personal trades, not company treasury transactions).
2025-07-16 English
DIRECTOR/PDMR SHAREHOLDING
Regulatory Filings
2025-07-15 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.